Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN)

Group 1: Company Overview - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases, emphasizing translating science into treatments that can meaningfully change patients' lives [6] Group 2: Recent Developments - Morgan Stanley analyst Terence Flynn raised the price target on Regeneron to $768 from $767, maintaining an Equal Weight rating, and expects policy concerns affecting biopharma to fade by 2026, shifting focus back to company fundamentals [2] - The Ministry of Health, Labour and Welfare in Japan granted marketing and manufacturing authorization for Dupixent (dupilumab) for treating bronchial asthma in children ages 6 to 11 with severe or refractory disease [3] - Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement, with over 60 clinical trials involving more than 10,000 patients across various chronic conditions linked to type 2 inflammation [4] Group 3: Ongoing Research - Sanofi and Regeneron are continuing to study dupilumab for a range of diseases driven by type 2 inflammation or other allergic processes, with Phase 3 trials underway for conditions such as chronic pruritus of unknown origin and allergic fungal rhinosinusitis [5]